Tasman Therapeutics Inc, a newly incorporated clinical-stage pharmaceutical company, announced on Thursday that is planning to raise USD175m in Series A funding.
The new funding is intended to support the late-stage clinical development and eventual commercialisation of R-107, an innovative extended-release oral ketamine tablet being investigated as a monotherapy for patients with Treatment-Resistant Depression (TRD). According to Tasman, R-107 represents a potential breakthrough in addressing the needs of individuals living with difficult-to-treat depression.
Tasman's pivotal Phase 3 ROCKET Program is set to begin patient enrolment in the second half of 2025. This is intended to generate crucial data on the safety, onset of effect and durability of a novel oral ketamine monotherapy designed for at-home administration. Tasman aims to present its findings to the FDA in 2027, paving the way for potential commercialisation in 2028.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval